Cargando…

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease

Lung Cancer is still one of the leading causes for cancer related death worldwide. The determination of an adequate therapeutic approach requests a precise staging, which contains computed tomography (CT) of the thorax, positron emission tomography computed tomography (PET-CT), cerebral magnetic res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menghesha, Hruy, Doerr, Fabian, Schlachtenberger, Georg, Estremadoyro, Andres Amorin, Töpelt, Karin, Wahlers, Thorsten, Hekmat, Khosro, Heldwein, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399512/ https://www.ncbi.nlm.nih.gov/pubmed/36033907 http://dx.doi.org/10.1016/j.rmcr.2022.101728

Ejemplares similares

Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
por: Doerr, Fabian, et al.
Publicado: (2022)

Redefining the role of surgery in early small-cell lung cancer
por: Doerr, Fabian, et al.
Publicado: (2022)

Der Stellenwert der Thymektomie ohne Thymom in der Therapie der Myasthenia gravis
por: Menghesha, Hruy, et al.
Publicado: (2021)

The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation
por: Menghesha, Hruy, et al.
Publicado: (2023)

Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review
por: Schlachtenberger, Georg, et al.
Publicado: (2022)

Adjuvant chemotherapy for locally advanced non-small cell lung cancer: still state of the art or an outdated therapy?
por: Schlachtenberger, Georg, et al.
Publicado: (2023)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Combination of European System for Cardiac Operative Risk Evaluation (EuroSCORE) and Cardiac Surgery Score (CASUS) to Improve Outcome Prediction in Cardiac Surgery
por: Doerr, Fabian, et al.
Publicado: (2015)

Inclusion of ‘ICU-Day’ in a Logistic Scoring System Improves Mortality Prediction in Cardiac Surgery
por: Doerr, Fabian, et al.
Publicado: (2015)

Preoperative risk stratification models fail to predict hospital cost of cardiac surgery patients
por: Badreldin, Akmal MA, et al.
Publicado: (2013)

Logistic Organ Dysfunction Score (LODS): A reliable postoperative risk management score also in cardiac surgical patients?
por: Heldwein, Matthias B, et al.
Publicado: (2011)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study
por: Liu, Wenliang, et al.
Publicado: (2023)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

A comparative study of four intensive care outcome prediction models in cardiac surgery patients
por: Doerr, Fabian, et al.
Publicado: (2011)

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy
por: Smith, Margaret R., et al.
Publicado: (2023)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

UICC Technical Report Series
por: Potten, C. S.
Publicado: (1976)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Narrowing the therapeutic window?—A case-control study on the influence of the COVID-19 pandemic on the primary UICC stage of NSCLC
por: Metelmann, Isabella B., et al.
Publicado: (2023)

Brief Report: Acetaminophen Reduces Neoadjuvant Chemoimmunotherapy Efficacy in Patients With NSCLC by Promoting Neutrophil Extracellular Trap Formation: Analysis From a Phase 2 Clinical Trial
por: Li, Chongwu, et al.
Publicado: (2023)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
por: Lu, Meng, et al.
Publicado: (2022)

Angiosarcoma of the Left Atrium: A Case Report
por: Schlachtenberger, Georg, et al.
Publicado: (2018)

Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

UICC-ARO Symposium at the UICC 2016 World Cancer Congress How Can We Mobilize Action to Realize UHC in Asia?
por: Akaza, Hideyuki, et al.
Publicado: (2017)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
por: Eichhorn, Florian, et al.
Publicado: (2019)

Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases: A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic Factors
por: Grapatsas, Konstantinos, et al.
Publicado: (2023)

The effect of fibre size on the in vivo activity of UICC crocidolite.
por: Wagner, J. C., et al.
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_8k49jnl2ud6o35v9e8amj6c9ed